Effects of Anastrozole on Breast Cancer in Postmenopausal Women
Author Information
Author(s): Anderson T J, Dixon J M, Stuart M, Sahmoud T, Miller W R
Primary Institution: Western General Hospital, Edinburgh, UK
Hypothesis
What are the effects of 12 weeks of neoadjuvant treatment with anastrozole on the histology of breast cancer in postmenopausal women?
Conclusion
Neoadjuvant treatment with anastrozole significantly alters the histopathology of breast tumors, but these changes do not always correlate with clinical response.
Supporting Evidence
- 18 out of 23 patients showed a clinical response to anastrozole treatment.
- Marked changes in histopathological features were observed in 15 out of 23 tumors.
- All tumors showed a reduction in Mib1 score after treatment.
Takeaway
This study shows that a medicine called anastrozole can change how breast cancer looks under a microscope, but those changes don't always mean the cancer is getting better.
Methodology
Postmenopausal women with large operable breast cancer were treated with anastrozole for 12 weeks, and tumor samples were analyzed before and after treatment.
Potential Biases
Potential bias due to the small number of patients and lack of power calculations for pathology parameters.
Limitations
The study had a small sample size and was a secondary analysis of a primary study.
Participant Demographics
Postmenopausal women aged 50 or over with large, operable, estrogen-receptor rich breast cancer.
Statistical Information
P-Value
0.59
Statistical Significance
p=0.59
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website